Indianapolis Business Journal

AUGUST 18-24, 2014

Eli Lilly and Co. once was a pioneer in biotech drugs and treating autoimmune diseases, but abandoned the fields in 1991. Subsequently, biotech autoimmune medicines have become best-sellers. This week, J.K. Wall details how Lilly has been trying to get back in the game. Also this week, Anthony Schoettle reports the Indianapolis Indians' stock buy-back offer might be undervaluing the franchise. And in A&E Etc., Lou Harry reviews Bar Rio.

Front PageBack to Top

Top StoriesBack to Top

FocusBack to Top

OpinionBack to Top

EDITORIAL: Public deserves full disclosure

The city might be negotiating a sweet deal for Indianapolis taxpayers over the proposed $500 million justice center to be built across from the Indianapolis Zoo on the former site of General Motors’ stamping plant. Or, taxpayers might be getting a bad deal.

Read More

LAMKIN: Tax tips for a reform-minded Pence

Determining governmental and tax structures is a major responsibility of state government. But, as we proceed into the 21st century, it is important to note that the size, density and distribution of our population have changed over the last 1-1/2 centuries.

Read More

How to upgrade International Motor Speedway

The quality of the racing entertainment at Indianapolis Motor Speedway is unsurpassed by any track [Aug. 4]. If the ultimate goal is to attract more fans, then Doug Boles must make their comfort a top priority.

Read More

In BriefBack to Top

PROXY CORNER: Noble Roman’s Inc.

Indianapolis-based Noble Roman’s Inc.sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations under the trade names “Noble Roman’s Pizza," “Noble Roman’s Take-N-Bake” and “Tuscano’s Italian Style Subs.”

Read More